Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADV7103 Long-term Extension in Cystinuria
NCT04137978Phase 3Withdrawn
- Sponsor
- Advicenne
- Start
- May 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of Sibnayal in cystinuria (CSNU), sponsored by Advicenne. Planned start May 2024; status: withdrawn.
02
Drugs
Sibnayal
03
Conditions
cystinuria (CSNU)
Beyond the preview
Go deeper on NCT04137978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04137978.